Dr Alessandra Tedeschi speaks to ecancer at EHA 2024 about her study the SEQUOIA trial (Arm D) evaluated the combination of zanubrutinib and venetoclax in treatment-naïve CLL/SLL patients with del(17p).

Preliminary results from 35 patients showed a high overall response rate of 96.8% with a median follow-up of 9.7 months.

The treatment was generally well-tolerated, with common adverse events including diarrhoea and neutropenia, and no reports of tumour lysis syndrome.

This combination therapy appears promising for high-risk del(17p) CLL/SLL patients.